Breaking News Bar

Business News and Information

With FDA approval in sight, why Aerie's keen on global strategy too

With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear